All In Biotech

Drug Trial Radar · NCT00106886

HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)

Last checked: Nov 20, 2026Latest source record: Sep 20, 2005 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 5,000 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

5,000

Actual

Start

Dec 1999

Primary completion

Not stated

Study completion Oct 2005

Sponsor

Lead sponsor
Hamilton Health Sciences CorporationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Canadian Institutes of Health Research (CIHR); Population Health Research Institute
First posted
Apr 1, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Prevention
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the HOPE-2 study is to determine whether long term supplementation with folic acid, vitamins B6 and B12 aimed at homocyst(e)ine reduction reduces the rates of major fatal and nonfatal cardiovascular events in patients with established cardiovascular disease and/or diabetes mellitus.

Conditions

  • Cardiovascular Disease
  • Myocardial Infarction
  • Stroke
  • Cancer

Interventions

  • Folic acid, vitamin B6 and B12 or placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The composite of cardiovascular death, myocardial infarction (MI) and stroke

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • McMaster University and Hamilton Health Sciences Corporation

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.